<i>TP53</i>‐altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity
Rory M. Shallis, Naval Daver, Jessica K. Altman, Robert P. Hasserjian, Hagop M. Kantarjian, Uwe Platzbecker, Valeria Santini, Andrew H. Wei, David A. Sallman, Amer M. Zeidan
Abstract
TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.
Topics & Concepts
MedicineMyeloid leukemiaMyelodysplastic syndromesClinical trialUnificationLeukemiaMyeloidOncologyCancer researchImmunologyInternal medicineBone marrowComputer scienceProgramming languageAcute Myeloid Leukemia ResearchSarcoma Diagnosis and TreatmentHematopoietic Stem Cell Transplantation